Surgical timing following neoadjuvant chemotherapy for breast cancer affects postoperative complication rates

被引:18
|
作者
Sutton, Thomas L. [1 ]
Johnson, Nathalie [2 ]
Schlitt, Alexander [3 ]
Gardiner, Stuart K. [4 ]
Garreau, Jennifer R. [2 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Surg, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97239 USA
[2] Legacy Canc Inst, Legacy Med Grp Surg Oncol, 1040 NW 22nd Ave,Suite 560, Portland, OR 97227 USA
[3] Pacific Northwest, Coll Osteopath Med, 200 Mullins Dr, Lebanon, OR 97355 USA
[4] Legacy Hlth, Legacy Res Inst, Devers Eye Inst, 1225 NE 2nd Ave, Portland, OR 97232 USA
关键词
Complications; Breast cancer; Time to surgery; Neoadjuvant chemotherapy; ANTINEOPLASTIC AGENTS; IMPACT; CYCLOPHOSPHAMIDE; SURGERY; DOXORUBICIN; ADRIAMYCIN; MASTECTOMY; DOCETAXEL; OUTCOMES; TIME;
D O I
10.1016/j.amjsurg.2020.02.061
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Neoadjuvant chemotherapy (NAC) is increasingly used in the treatment of breast cancer. The time interval from last dose of cytotoxic chemotherapy to surgery (TTS) can vary widely. We aimed to evaluate the effect of TTS on postoperative complications. Methods: A retrospective review for women treated with NAC at our institution between January 2011 through December 2016 was performed. Charts were reviewed for postoperative wound complications, and multivariate analysis was performed. Results: 455 patients were identified. Median TTS was 30 days (range 11-228). On multivariate analysis, TTS of less than 28 days was associated with 70% higher odds of any wound complication (p < 0.05). Increasing age had the strongest association with the presence of any wound complication (p < 0.0001). The majority of complications were treated in the outpatient setting (n = 80, 83%). Conclusion: Following NAC for breast cancer, TTS less than 28 days is a risk factor for postoperative wound complications; however, the majority of complications are minor and treated in the outpatient setting. Additional data are needed to determine optimal TTS for oncologic outcomes. (C) 2020 Published by Elsevier Inc.
引用
收藏
页码:741 / 745
页数:5
相关论文
共 50 条
  • [21] The surgical management of patients following neoadjuvant chemotherapy for locally advanced breast cancer
    Sauven, P
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (18) : 2371 - 2374
  • [22] Factors Associated With Surgical Modality Following Neoadjuvant Chemotherapy in Patients with Breast Cancer
    Li, Xin
    Yan, Changjiao
    Xiao, Jingjing
    Xu, Xin
    Li, Yike
    Wen, Xinxin
    Wei, Hongliang
    CLINICAL BREAST CANCER, 2021, 21 (05) : E611 - E617
  • [23] Surgical site infection in immediate breast reconstruction: Does chemotherapy timing make a difference?
    Chattha, Anmol S.
    Cohen, Justin B.
    Bucknor, Alexandra
    Chen, Austin D.
    Tobias, Adam M.
    Lee, Bernard T.
    Lin, Samuel J.
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (07) : 1440 - 1446
  • [24] Utility of neoadjuvant chemotherapy in the treatment of operable breast cancer
    Read, Rebecca L.
    Flitcroft, Kathy
    Snook, Kylie L.
    Boyle, Frances M.
    Spillane, Andrew J.
    ANZ JOURNAL OF SURGERY, 2015, 85 (05) : 315 - 320
  • [25] Neoadjuvant chemotherapy for early breast cancer
    Mieog, J. Sven D.
    van de Velde, Cornelis J. H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (09) : 1423 - 1434
  • [26] Assessment of Radiotherapy as a Standalone Treatment Following Neoadjuvant Chemotherapy in Nonmetastatic Breast Cancer
    Loap, Pierre
    Kirova, Youlia
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (01): : 16 - 20
  • [27] From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?
    Chen, Qichen
    Mao, Rui
    Zhao, Jianjun
    Bi, Xinyu
    Li, Zhiyu
    Huang, Zhen
    Zhang, Yefan
    Zhou, Jianguo
    Zhao, Hong
    Cai, Jianqiang
    CANCER MEDICINE, 2020, 9 (21): : 7849 - 7862
  • [28] Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger
    Eralp, Yesim
    Smith, Terry L.
    Altundag, Kadri
    Kau, Shu-Wan
    Litton, Jennifer
    Valero, Vicente
    Buzdar, Aman
    Hortobagyi, Gabriel N.
    Arun, Banu
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (01) : 141 - 148
  • [29] Tailoring Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Historical Prospective Study
    Zer, Alona
    Rizel, Shulamit
    Braunstein, Rony
    Yerushalmi, Rinat
    Hendler, Daniel
    Neimann, Victoria
    Cioreuru, Noa
    Sulkes, Aaron
    Stemmer, Salomon M.
    CHEMOTHERAPY, 2012, 58 (02) : 95 - 101
  • [30] Patients' experiences with decisions on timing of chemotherapy for breast cancer
    de Ligt, K. M.
    Spronk, P. E. R.
    van Bommel, A. C. M.
    Peeters, M. T. F. D. Vrancken
    Siesling, S.
    Smorenburg, C. H.
    BREAST, 2018, 37 : 99 - 106